Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) EBITDA (2018 - 2025)

Historic EBITDA for AVITA Medical (RCEL) over the last 8 years, with Q4 2025 value amounting to -$10.4 million.

  • AVITA Medical's EBITDA fell 452.95% to -$10.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$42.5 million, marking a year-over-year increase of 2483.88%. This contributed to the annual value of -$42.5 million for FY2025, which is 2484.23% up from last year.
  • AVITA Medical's EBITDA amounted to -$10.4 million in Q4 2025, which was down 452.95% from -$9.2 million recorded in Q3 2025.
  • AVITA Medical's EBITDA's 5-year high stood at -$4.7 million during Q2 2021, with a 5-year trough of -$17.2 million in Q1 2024.
  • Over the past 5 years, AVITA Medical's median EBITDA value was -$9.9 million (recorded in 2023), while the average stood at -$9.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 6387.93% in 2021, then crashed by 10773.53% in 2023.
  • AVITA Medical's EBITDA (Quarter) stood at -$5.9 million in 2021, then rose by 0.69% to -$5.9 million in 2022, then tumbled by 107.74% to -$12.3 million in 2023, then increased by 18.87% to -$10.0 million in 2024, then dropped by 4.53% to -$10.4 million in 2025.
  • Its EBITDA stands at -$10.4 million for Q4 2025, versus -$9.2 million for Q3 2025 and -$11.1 million for Q2 2025.